Traditional and novel approaches to flavivirus vaccines.

Yellow fever, dengue, Japanese encephalitis and tick-borne encephalitis viruses are the medically most important members of the Flavivirus genus composed primarily of arboviruses. In this paper, we review the commercially available traditional flavivirus vaccines against yellow fever, Japanese encephalitis, and tick-borne encephalitis, as well as modern approaches to flavivirus vaccines. Formalin inactivation technology has been employed to produce killed vaccines. Flaviviruses have been attenuated by multiple passages in animal tissues and cell cultures to produce empirical live attenuated vaccines. The use of traditional methods is being pursued to develop vaccines against other flavivirus diseases, such as dengue, and to improve existing vaccines, such as for Japanese encephalitis. With the recent development of infectious clones, rational approaches to attenuated flavivirus vaccines have employed the introduction of specific mutations into wild type viruses and chimerisation between different viruses. Novel methods for delivery of live vaccines, such as inoculation of infectious DNA or RNA, have been described. Other approaches, such as the construction of protein subunit, expression vector-based and naked DNA vaccines, have been proposed to create alternate vaccine candidates.

[1]  R. Garratt,et al.  Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. , 2002, Journal of molecular biology.

[2]  B. Falgout,et al.  Construction of a Full Length Infectious Clone for Dengue-1 Virus Western Pacific,74 Strain , 2004, Virus Genes.

[3]  F. Heinz,et al.  Proteolytic activation of tick-borne encephalitis virus by furin , 1997, Journal of virology.

[4]  M. Bray,et al.  Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Harrison,et al.  The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution , 1995, Nature.

[6]  H. Sumiyoshi,et al.  Infectious Japanese encephalitis virus RNA can be synthesized from in vitro-ligated cDNA templates , 1992, Journal of virology.

[7]  D. Vaughn,et al.  A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. , 2001, Vaccine.

[8]  A. Pletnev Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3' deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice. , 2001, Virology.

[9]  C. Huang,et al.  Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine , 2000, Journal of Virology.

[10]  J. Roehrig,et al.  New Mouse Model for Dengue Virus Vaccine Testing , 1999, Journal of Virology.

[11]  T. Monath,et al.  Yellow fever: an update. , 2001, The Lancet. Infectious diseases.

[12]  R. Karron,et al.  A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. , 2001, The American journal of tropical medicine and hygiene.

[13]  M. Bray,et al.  Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Vaughn,et al.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. , 2001, The American journal of tropical medicine and hygiene.

[15]  F. Ennis,et al.  Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes , 1989, Journal of virology.

[16]  Gary J. Nabel,et al.  New Generation Vaccines , 1990 .

[17]  I. Tokimatsu,et al.  Genetic Determinants Responsible for Acquisition of Dengue Type 2 Virus Mouse Neurovirulence , 1998, Journal of Virology.

[18]  R. Compans,et al.  Regulation of the late events in flavivirus protein processing and maturation. , 1993, Virology.

[19]  M. Bray,et al.  Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Bray,et al.  Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge , 1996, Journal of virology.

[21]  D. Gubler,et al.  Dengue and dengue hemorrhagic fever : Its history and resurgence as a global public health problem , 1997 .

[22]  F. Guirakhoo,et al.  Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. , 2002, Virology.

[23]  A. Barrett,et al.  Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants. , 1998, Virology.

[24]  M. Lobigs,et al.  Mechanism of Virulence Attenuation of Glycosaminoglycan-Binding Variants of Japanese Encephalitis Virus and Murray Valley Encephalitis Virus , 2002, Journal of Virology.

[25]  C. Mandl,et al.  Capsid Protein C of Tick-Borne Encephalitis Virus Tolerates Large Internal Deletions and Is a Favorable Target for Attenuation of Virulence , 2002, Journal of Virology.

[26]  B. Murphy,et al.  Chemical Mutagenesis of Dengue Virus Type 4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or Human Liver Cells and Attenuated in Mice , 2001, Journal of Virology.

[27]  A. Khromykh Replicon-based vectors of positive strand RNA viruses. , 2000, Current opinion in molecular therapeutics.

[28]  C. Rice,et al.  Genetic Interaction of Flavivirus Nonstructural Proteins NS1 and NS4A as a Determinant of Replicase Function , 1999, Journal of Virology.

[29]  C. Huang,et al.  Development of New Vaccines against Dengue Fever and Japanese Encephalitis , 2001, Intervirology.

[30]  B. Falgout,et al.  Derivation and Characterization of a Dengue Type 1 Host Range-Restricted Mutant Virus That Is Attenuated and Highly Immunogenic in Monkeys , 2002, Journal of Virology.

[31]  Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice , 1995, Journal of virology.

[32]  M. Bray,et al.  Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice , 1993, Journal of virology.

[33]  P. McMinn,et al.  Characterization of infectious Murray Valley encephalitis virus derived from a stably cloned genome-length cDNA. , 1999, The Journal of general virology.

[34]  F. Ennis,et al.  Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8- cytotoxic T-cell clones , 1994, Journal of virology.

[35]  F. Ennis,et al.  Dengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones , 1991, Journal of virology.

[36]  M. Cetron,et al.  Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases , 2001, The Lancet.

[37]  S. Punyagupta,et al.  Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. , 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[38]  T. Tsai New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. , 2000, Vaccine.

[39]  A. Rothman,et al.  Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. , 2002, Virology.

[40]  A. Barrett Current Status of Flavivirus Vaccines , 2001, Annals of the New York Academy of Sciences.

[41]  J. An,et al.  Development of a novel mouse model for dengue virus infection. , 1999, Virology.

[42]  Peter F. Stadler,et al.  Spontaneous and Engineered Deletions in the 3′ Noncoding Region of Tick-Borne Encephalitis Virus: Construction of Highly Attenuated Mutants of a Flavivirus , 1998, Journal of Virology.

[43]  R. Andino,et al.  Recombinant Yellow Fever Viruses Are Effective Therapeutic Vaccines for Treatment of Murine Experimental Solid Tumors and Pulmonary Metastases , 2000, Journal of Virology.

[44]  E. Paoletti,et al.  Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. , 1991, Virology.

[45]  F. Guirakhoo,et al.  Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. , 2001, Virology.

[46]  F. Guirakhoo,et al.  Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE) , 2001, Journal of Virology.

[47]  J. Stephenson,et al.  Defective adenoviruses as novel vaccines for the Flaviviridae. , 1998, Clinical and diagnostic virology.

[48]  S. Halstead,et al.  Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. , 1989, Reviews of infectious diseases.

[49]  E. Chungue,et al.  Dengue virus inhibits human hematopoietic progenitor growth in vitro. , 1997, The Journal of infectious diseases.

[50]  S. Vázquez,et al.  Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. , 2001, Virus research.

[51]  T. Monath,et al.  Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases , 2001, The Lancet.

[52]  A. Pletnev,et al.  Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Sabin Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.

[54]  C. Rice,et al.  Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation , 1997, Journal of virology.

[55]  E. Paoletti,et al.  Recognition of dengue virus NS1-NS2a proteins by human CD4+ cytotoxic T lymphocyte clones. , 1997, Virology.

[56]  Gorbunov Ma,et al.  [Comparative study of inactivated cultured vaccines against tick-borne encephalitis manufactured in Russia and in Austria by the "Immuno" firm]. , 1996 .

[57]  R. Padmanabhan,et al.  Synthesis and characterization of an infectious dengue virus type-2 RNA genome (New Guinea C strain). , 1995, Gene.

[58]  A. Rothman,et al.  Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. , 2001, Vaccine.

[59]  F. Guirakhoo,et al.  Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates , 2000, Journal of Virology.

[60]  H. Guzmán,et al.  Immunization with Heterologous Flaviviruses Protective Against Fatal West Nile Encephalitis , 2002, Emerging infectious diseases.

[61]  J. Sadoff,et al.  Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. , 1996, The Journal of infectious diseases.

[62]  C. Mandl,et al.  Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH , 1995, Journal of virology.

[63]  C. Lai,et al.  Mutational analysis of the octapeptide sequence motif at the NS1-NS2A cleavage junction of dengue type 4 virus , 1992, Journal of virology.

[64]  D. Vaughn,et al.  Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. , 2001, Vaccine.

[65]  C. Huang,et al.  Attenuation Markers of a Candidate Dengue Type 2 Vaccine Virus, Strain 16681 (PDK-53), Are Defined by Mutations in the 5′ Noncoding Region and Nonstructural Proteins 1 and 3 , 2000, Journal of Virology.

[66]  E. Konishi,et al.  Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles , 2001, Journal of Virology.

[67]  T. Monath Prospects for Development of a Vaccine against the West Nile Virus , 2001, Annals of the New York Academy of Sciences.

[68]  M. Crabtree,et al.  Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. , 2000, The American journal of tropical medicine and hygiene.

[69]  I. Kurane,et al.  Immunity and immunopathology in dengue virus infections. , 1992, Seminars in immunology.

[70]  F. Ennis,et al.  Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones , 1996, Journal of virology.

[71]  C. Mandl,et al.  Infectious cDNA clones of tick-borne encephalitis virus European subtype prototypic strain Neudoerfl and high virulence strain Hypr. , 1997, The Journal of general virology.

[72]  A. Rothman,et al.  Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes , 1993, Journal of virology.

[73]  I. Zhulin,et al.  Positional cloning of the murine flavivirus resistance gene , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[74]  A. Helenius,et al.  Folding and Dimerization of Tick-Borne Encephalitis Virus Envelope Proteins prM and E in the Endoplasmic Reticulum , 2002, Journal of Virology.

[75]  A. Davidson,et al.  Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA. , 1998, The Journal of general virology.

[76]  A. Davidson,et al.  Mutagenesis of the Dengue Virus Type 2 NS3 Protein within and outside Helicase Motifs: Effects on Enzyme Activity and Virus Replication , 2001, Journal of Virology.

[77]  A. Barrett,et al.  Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys , 2000, Journal of Virology.

[78]  D. Vaughn,et al.  West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Robert H Levis,et al.  Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast , 1997, Journal of virology.

[80]  D. Trent,et al.  Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. , 1988, Vaccine.

[81]  C. Kunz Tick-borne encephalitis in Europe. , 1992, Acta Leidensia.

[82]  P. Mason,et al.  Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. , 1995, Virology.

[83]  E. G. Westaway,et al.  Completion of Kunjin virus RNA sequence and recovery of an infectious RNA transcribed from stably cloned full-length cDNA , 1994, Journal of virology.

[84]  J. H. Bauer,et al.  THE TRANSMISSION OF YELLOW FEVER TO MACACUS RHESUS: PRELIMINARY NOTE , 1928 .

[85]  T. Mizutani,et al.  Evaluation of European tick-borne encephalitis virus vaccine against recent Siberian and far-eastern subtype strains. , 2001, Vaccine.

[86]  R. Chanock,et al.  Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys , 1996, Journal of virology.

[87]  E. Paoletti,et al.  Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. , 1994, Vaccine.

[88]  Interaction of Yellow Fever Virus French Neurotropic Vaccine Strain with Monkey Brain: Characterization of Monkey Brain Membrane Receptor Escape Variants , 2000, Journal of Virology.

[89]  Michael W. Parker,et al.  Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. , 1999, Science.

[90]  D. Gubler,et al.  Dengue and Dengue Hemorrhagic Fever , 1998, Clinical Microbiology Reviews.

[91]  F. Guirakhoo,et al.  Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. , 2002, Vaccine.

[92]  J. H. Strauss,et al.  Chimeric Yellow Fever/Dengue Virus as a Candidate Dengue Vaccine: Quantitation of the Dengue Virus-Specific CD8 T-Cell Response , 2000, Journal of Virology.

[93]  M. Bray,et al.  Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice , 1991, Journal of virology.

[94]  R. Jou,et al.  Screening of Protective Antigens of Japanese Encephalitis Virus by DNA Immunization: a Comparative Study with Conventional Viral Vaccines , 1999, Journal of Virology.

[95]  C. Rice,et al.  Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties , 1999, Journal of Virology.

[96]  Tran Truong,et al.  Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. , 1996, The American journal of tropical medicine and hygiene.

[97]  E. Marth,et al.  Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination. , 2001, Vaccine.

[98]  K. Hanley,et al.  Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in Mosquitoes , 2001, Journal of Virology.

[99]  A. Pletnev,et al.  Growth-restricted dengue virus mutants containing deletions in the 5' noncoding region of the RNA genome. , 1995, Virology.

[100]  E. Paoletti,et al.  Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. , 1992, Virology.

[101]  C. Mandl,et al.  Sequence of the genes encoding the structural proteins of the low-virulence tick-borne flaviviruses Langat TP21 and Yelantsev. , 1991, Virology.

[102]  C. Mandl,et al.  In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model , 1998, Nature Medicine.

[103]  C. Rice,et al.  Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. , 1989, The New biologist.

[104]  E. Konishi,et al.  Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. , 2000, Vaccine.

[105]  A. Barrett,et al.  Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. , 1999, Vaccine.

[106]  J. Roehrig,et al.  Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. , 1997, Virology.

[107]  C. Rice,et al.  Mutagenesis of the NS2B-NS3-Mediated Cleavage Site in the Flavivirus Capsid Protein Demonstrates a Requirement for Coordinated Processing , 1999, Journal of Virology.

[108]  C. Mandl,et al.  Adaptation of Tick-Borne Encephalitis Virus to BHK-21 Cells Results in the Formation of Multiple Heparan Sulfate Binding Sites in the Envelope Protein and Attenuation In Vivo , 2001, Journal of Virology.

[109]  V. Yamshchikov,et al.  A ‘minimal’ approach in design of flavivirus infectious DNA , 2001, Virus Research.

[110]  P. Mason Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells , 1989, Virology.

[111]  B. Murphy,et al.  Paired Charge-to-Alanine Mutagenesis of Dengue Virus Type 4 NS5 Generates Mutants with Temperature-Sensitive, Host Range, and Mouse Attenuation Phenotypes , 2002, Journal of Virology.

[112]  F. Guirakhoo,et al.  Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine , 2001, Journal of Virology.

[113]  M. Lobigs,et al.  Substitutions at the Putative Receptor-Binding Site of an Encephalitic Flavivirus Alter Virulence and Host Cell Tropism and Reveal a Role for Glycosaminoglycans in Entry , 2000, Journal of Virology.

[114]  T. Monath Editorial: jennerian vaccination against West Nile virus. , 2002, The American journal of tropical medicine and hygiene.

[115]  N. Kanesa-thasan,et al.  Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines. , 2002, The American journal of tropical medicine and hygiene.

[116]  M. Bras,et al.  Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[117]  A. Barrett,et al.  Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. , 1999, Virology.

[118]  S. Halstead,et al.  Pathogenesis of dengue: challenges to molecular biology. , 1988, Science.

[119]  D. Harrich,et al.  Kunjin Virus Replicon Vaccine Vectors Induce Protective CD8+ T-Cell Immunity , 2002, Journal of Virology.

[120]  A. Pletnev,et al.  Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus. , 2000, Virology.

[121]  R. Compans,et al.  An infectious clone of the West Nile flavivirus. , 2001, Virology.

[122]  R. Rico-Hesse,et al.  Dengue Virus Structural Differences That Correlate with Pathogenesis , 1999, Journal of Virology.

[123]  W. Rawlinson,et al.  Hepatitis and death following vaccination with 17D-204 yellow fever vaccine , 2001, The Lancet.

[124]  C. Mandl,et al.  Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E , 2001, Journal of Virology.

[125]  T. Monath,et al.  Dengue: the risk to developed and developing countries. , 1994, Proceedings of the National Academy of Sciences of the United States of America.